<DOC>
	<DOCNO>NCT00726986</DOCNO>
	<brief_summary>RATIONALE : Sorafenib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , cisplatin etoposide , work different way stop growth tumor cell , either kill cell stop divide . Giving sorafenib together combination chemotherapy may kill tumor cell . PURPOSE : This phase II trial study well give sorafenib together cisplatin etoposide work treat patient extensive-stage small cell lung cancer .</brief_summary>
	<brief_title>Sorafenib , Cisplatin , Etoposide Treating Patients With Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate 1-year progression-free survival patient extensive-stage small cell lung cancer treat sorafenib tosylate combination cisplatin etoposide . - To evaluate 1-year overall survival response rate patient . - To evaluate safety drug patient . OUTLINE : This multicenter study . Patients receive cisplatin IV 30-60 minute day 1 etoposide IV 60 minute day 1-3 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients also receive oral sorafenib tosylate twice daily begin day 1 course 1 continue 1 year absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis extensivestage small cell lung cancer No untreated brain metastasis No active symptom relate brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 Hemoglobin ≥ 9.0 g/dL ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT AST ≤ 2.5 time ULN ( ≤ 5 time ULN patient liver involvement ) Creatinine ≤ 1.5 time ULN INR &lt; 1.5 PT/PTT normal No history cardiac disease , include follow : NYHA class IIIIV congestive heart failure Unstable angina ( i.e. , anginal symptom rest ) Onset angina within past 3 month Myocardial infarction within past 6 month No cardiac ventricular arrhythmia require antiarrhythmic therapy No uncontrolled hypertension , define systolic blood pressure ( BP ) &gt; 150 mm Hg diastolic BP &gt; 90 mm Hg , despite optimal medical management No thrombolic embolic event , cerebrovascular accident transient ischemic attack , within past 6 month No pulmonary hemorrhage/bleeding event ≥ CTCAE grade 2 within past 4 week No hemorrhage/bleeding event ≥ CTCAE grade 3 within past 4 week No know HIV infection chronic hepatitis B C infection No active clinically serious infection &gt; CTCAE grade 2 No serious nonhealing wound , ulcer , bone fracture No evidence history bleed diathesis coagulopathy No significant traumatic injury within past 4 week No know suspect allergy sorafenib tosylate drug give study No condition would impair patient 's ability swallow whole pill No know malabsorption problem Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception Male patient must use effective contraception ≥ 3 month completion sorafenib tosylate PRIOR CONCURRENT THERAPY : Prior radiotherapy brain allow No prior chemotherapy More 4 week since prior major surgery open biopsy No concurrent Hypericum perforatum ( St. John 's wort ) rifampin Concurrent anticoagulation treatment , warfarin heparin , allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>extensive stage small cell lung cancer</keyword>
</DOC>